Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone onworsening of diabetic retinopathy in a randomized clinical trial

JAMA Ophthalmology

Volumn 131, Issue 8, 2013, Pages 1033-1040

  Bressler, Susan B ^b   Qin, Haijing ^a   Melia, Michele ^a   Bressler, Neil M ^b   Beck, Roy W ^a   Chan, Clement K ^c   Grover, Sandeep ^d   Miller, David G ^c  

^a JAEB CENTER FOR HEALTH RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Southern California Desert Retina Consultants ^*

^d UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TRIAMCINOLONE;

ARTICLE; CATARACT; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE EXACERBATION; ENDOPHTHALMITIS; GLAUCOMA; HUMAN; LASER COAGULATION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; VISUAL DISORDER; VITRECTOMY; VITREOUS HEMORRHAGE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 84881646605     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.4154     Document Type: Article

References (19)

1. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology. 1991;98(5)(suppl):823-833.
2. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology. 1981;88(7):583-600.
3. Googe J, Brucker AJ, Bressler NM, et al Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6):1009-1027.
4. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275-278.
5. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(1):155-158.
6. Mason JO III, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(4):685-688.
7. Adamis AP, Altaweel M, Bressler NM, et al Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006;113(1):23-28.
8. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372.e5. doi:10.1016/j.ophtha .2005.11.019.
9. González VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol. 2009;93(11):1474-1478.
10. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077. e35. doi:10.1016/j.ophtha.2010.0.031.
11. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE [published online May 23, 2013]. Ophthalmology. doi:10.1016/j.ophtha.2013.02.034.
12. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695.e1-1695.e15. doi:10.1016/j.ophtha.2006.05.064.
13. IpMS, Domalpally A, Hopkins JJ,Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-1152.
14. Bressler NM, Edwards AR, Beck RW, et al Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009;127(12):1566-1571.
15. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: Adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. 2003;135(2):194-205.
16. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology. 1991;98(5)(suppl):786-806.
17. Lee EW,Wei LJ, Amato DA. Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations. Dordrecht, the Netherlands: Kluwer Academic; 1992:237-247.
18. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE study group. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
19. Nguyen QD, Brown DM, Marcus DM, et al RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4): 789-801.